GLP-1 targeted therapy may help diabetes patients
March 15th 2014The role of ophthalmologists will become increasingly more vital in the management of type 2 diabetes as the numbers of patients with the disease is projected to double by 2030. Exenatide may prove to be an important adjunct to current oral anti-diabetes drugs.
CXL-LASIK reinforces cornea stability
March 15th 2014Performing collagen crosslinking as a concurrent primary LASIK procedure-show data from comparative studies of patients with hyperopia and myopia at risk for ectasia or regression postLASIK-increases postoperative refractive and keratometric stability.
Bevacizumab more cost-effective for ROP than laser
March 12th 2014Treating retinopathy of prematurity (ROP) has a great value in societal terms due to the potentially long lifespans ahead of these patients. However, a comparison of bevacizumab (Avastin, Genentech) and laser for treating ROP found that drug therapy was more cost effective than laser, even with extended follow-up periods, according to Michael J. Geske, MD.
Why lab evaluation is rarely needed in pediatric cataract patients
March 5th 2014Although there is a long list of systemic disorders that can lead to pediatric cataracts, rarely does the ophthalmologist need to initiate laboratory evaluation to diagnose an underlying cause, according to Daniel E. Neely, MD.
Exploring new therapies for neovascular AMD
March 1st 2014Combination treatment for neovascular age-related macular degeneration is more likely to provide more favorable results by eliminating vascular endothelial growth factor and possibly causing true regression of choroidal neovascularization, reducing the risk of visual loss.
Experts weigh-in on treatment options for neovascular AMD
March 1st 2014With several options available for improving vision in patients with neovascular age-related macular degeneration, the decision about which agent to use might take into account information on resolution of macular edema, cost, and safety.
B+L femtosecond laser platform cleared for corneal incisions
March 1st 2014The FDA has granted 510(k) clearance to Bausch + Lomb’s femtosecond laser platform (Victus) for the creation of incisions in the cornea of patients undergoing cataract surgery or other ophthalmic treatments requiring incisions in the cornea.